



**Press Release
New Delhi
January 4, 2008**

For Immediate Release

WHO pre-qualifies Panacea Biotec for supply of EasyFour and Ecovac Vaccines

Panacea Biotec has been pre-qualified by WHO for supplying their innovative combination vaccines for pediatric immunization- EasyFour (DTP + Hib) and Ecovac (DTP + Hep B). In a notification, WHO has advised the UN procuring agencies regarding the acceptability of these vaccines worldwide. Panacea Biotec is already a pre-qualified supplier of OPV and Hepatitis-B vaccines to UN agencies.

Panacea Biotec has been playing an imperative role in immunization through its novel and innovative, world's first fully liquid vaccine with brands such as, 'Easy Four' & 'Easy Five', for over 3 years. It has partnered with WHO & UNICEF with a mission of supporting the cause of maximizing coverage of vaccines under the Expanded Program on Immunization (EPI) for more than a decade.

The combined demand of all combination pediatric vaccines worldwide was valued at USD 600 million in 2005 and is estimated to grow up to USD 1.6 billion by 2012.

Speaking on the occasion, **Mr. Rajesh Jain, JMD, Panacea Biotec** says, **“Panacea Biotec has built an innovative portfolio of combination vaccines which has enabled it achieve a leadership position in just about two years of its launch in India. With this pre-qualification by WHO, Panacea Biotec would participate in a large global market of combination vaccines for pediatric immunization.”**

Panacea Biotec inaugurated its ultra modern, Greenfield construction, vaccine production plant at Baddi, H.P., with over Rs. 100 Crore (approx. USD 25 million) investment in Sept'07, having capacity of more than 1 billion doses per annum, to cater to domestic and global markets. With this latest state-of-art facility, the total capacity to produce vaccines by Panacea Biotec would be doubled to two billion doses per annum. The commercial production is expected to commence in next financial year.

Panacea Biotec Ltd.

B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-26940621, 26940199, 41679070, Email: corporate@panaceabiotec.com

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Website: www.panacea-biotec.com



About Panacea Biotec

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey 2007) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has four research and development centers. It has around 2800 employees including over 250 highly skilled scientists. The company also has 19 product patents, valid in more than 60 countries worldwide.

For further details please contact:

Mr. Pradeep Kumar Jain
GM - Corporate Communications & Govt. Affairs
Mobile: 09313482886
Land Line: 011-41678000; Fax: 011-41679096
Email: pradeepjain@panaceabiotec.com
Website: www.panaceabiotec.com

Panacea Biotec Ltd.

B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-26940621, 26940199, 41679070, Email: corporate@panaceabiotec.com

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Website: www.panacea-biotec.com